Compositions and methods for therapeutic or vaccine delivery
AssigneeGenVivo, Inc.
InventorsJacqueline FISCHER-LOUGHEED, Bradford H. STEELE, Cecilia ROH, Robert G. JOHNSON, JR.
Life of this patent
Estimating the term…
Abstract
Described herein are compositions for delivering a therapeutic or vaccine. Also described herein are methods for using the compositions described herein for delivering a therapeutic or a vaccine.
Claims21
-84. (canceled)
A recombinant virus comprising a recombinant retroviral vector, the recombinant retroviral vector comprising a murine leukemia virus (MLV) comprising a first nucleic acid sequence encoding a mutant integrase and a second nucleic acid sequence encoding at least one payload, the mutant integrase, when compared to a wild-type integrase, comprises at least one mutation in a Mg2+ binding motif of a catalytic core domain, wherein the mutant integrate has defective retroviral integration activity as compared to a recombinant retroviral vector comprising the wild-type integrase having a sequence of SEQ ID NO:
- 1;
- and the at least one payload is selected from the group consisting of a cytokine, a thymidine kinase, and an antigen.
A cell comprising a recombinant virus, the recombinant virus comprising a recombinant viral vector, the recombinant retroviral vector comprising a first nucleic acid sequence encoding a mutant integrase and a second nucleic acid sequence encoding at least one payload, the mutant integrase, when compared to a wild-type integrase, comprises at least one mutation in a Mg2+ binding motif of a catalytic core domain, wherein the mutant integrate has defective retroviral integration activity as compared to a recombinant retroviral vector comprising the wild-type integrase having a sequence of SEQ ID NO:
- 1;
- and the at least one payload selected from the group consisting of a cytokine, a thymidine kinase, and an antigen.
Dependencies are inferred from the claim text.